27 papers · ranked by Valyu relevance
Yaser Alduais, Haijun Zhang, Fan Fan, Jing Chen + 1 more
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy, immunotherapy, or molecularly targeted therapy is used to treat NSCLC. Nevertheless, many patients who accept surgery likely develop distant…
Songzhen LI, Tianhang SHAO, Shuyang YAO
寡转移是早期转移和广泛转移之间的过渡状态，肿瘤负荷有限，具备独特的肿瘤生物学行为。由于转移灶的数量和受累器官的数量相对有限，经过积极的系统治疗和局部巩固治疗，有潜在治愈的机会。随着分子靶向药物治疗和免疫治疗的飞速发展，非小细胞肺癌（non-small cell lung cancer, NSCLC）寡转移的综合治疗越来越受到重视。本文对NSCLC寡转移的定义、治疗进展以及存在的诸多挑战进行综述，以期为临床诊疗提供思路。
Beata Smolarz, Honorata Łukasiewicz, Dariusz Samulak, Ewa Piekarska + 3 more
'Radosław Kołaciński' 'Hanna Romanowicz' 'Verena Tretter'] Lung cancer is one of the most common malignant cancers in most countries and is the leading cause of death among cancer diseases worldwide. Despite constant progress in diagnosis and therapy, survival rates of patients diagnosed with lung cancer remain…
Authors not listed
非小细胞肺癌是发病率及致死率最高的恶性肿瘤之一。约20%-50%会发生远处转移，最常见的转移部位为脑、骨、肝及肾上腺。寡转移状态是一段肿瘤生物侵袭性较温和的时期，存在于局限性原发灶与广泛性转移之间的过渡阶段，转移瘤数目有限并且转移器官具有特异性。“寡转移”来源于微转移，肿瘤细胞已具有器官特异性，但尚不具备全身播散的遗传倾向。治疗寡转移状态的关键是局部控制，需要兼顾预防远处转移、治疗隐匿性转移灶、治疗寡转移灶和全身治疗结束后清除残留癌灶四个方面。本文旨在对“寡转移”概念在非小细胞肺癌常见转移脏器治疗中的应用作一综述。
Benjamin Schneider, Sébastien Benzekry, Jonathan P. Mochel
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first…
Benjamin Schneider, Sébastien Benzekry, Jonathan P. Mochel
Insights from Joint Modeling and Large-Scale Data Analysis Authors: ['Benjamin Schneider' 'Sébastien Benzekry' 'Jonathan P. Mochel'] - Non-small cell lung cancer (NSCLC) is a leading cause of mortality. Many treatments for NSCLC rely on combination therapy with bevacizumab, an anti-VEGF adjunct. - Evidence is presented…
Man Jiang, Yuan-De Tan
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, partly due to limited early detection strategies and incomplete understanding of tumor-suppressive mechanisms. In our previous work, we identified 26 tumor suppressor (TS) genes and characterized their biological functions and…
Lian Yang, Ming Xiao, Xian Li, Yalan Wang
TTF1 and ΔNp63/p40 have been used to differentiate ADC and SQC in hypofractionated NSCLC because of their sensitivity and specificity. There are few cases where TTF1 and ΔNp63/p40 are expressed together in the same tumour cells, and little is known about the clinicopathological features, treatment and prognosis of such…
Hezheng Lyu, Hassan Gharibi, Bohdana Sokolova, Anna Voiland + 5 more
Knowledge of the targets of therapeutic compounds is vital for understanding their action mechanisms and side effects, but such valuable data is seldom available. The multiple complementary techniques needed for comprehensive target characterization must combine data reliability with sufficient analysis throughput.…
Runyang Yin, Jing Gao, Yang Liu
Osimertinib resistance in Non-Small-Cell Lung Cancers (NSCLC) is a difficult problem to be solved in clinic. Formononetin is one of the main isoflavone components, which has strong anti-cancer effects in NSCLC. However, the potential effects and the mechanisms of Formononetin to counteract the Osimertinib resistant in…
Mahtab Darvish, Ryan Trask, Patrick Tallon, Mélina Khansari + 3 more
'Lei Ren' 'Michelle Hershman' 'Bardia Yousefi'] Lung cancer is the primary cause of cancer-related mortality, claiming approximately 1.79 million lives globally in 2020, with an estimated 2.21 million new cases diagnosed within the same period. Among these, Non-Small Cell Lung Cancer (NSCLC) is the predominant subtype…
Shubham Singh, Sangeeta Saxena, Himani Sharma, Gaurav Gupta + 2 more
'Kamal Dua' 'Sachin Kumar Singh'] According to Global Observatory Cancer (GLOBOCAN) 2020, the number of new cases of cancer diagnosed in 2020 was about 19.3 million and among them, 10.0 million people died. GLOBOCAN predicts that the number of cancer cases will increase up to 28.4 million by 2040 (Sung et al.…
Chen-Yang Huang, Nanhai Jiang, Meixin Shen, Gillianne Lai + 19 more
Unlike smoking-related non-small cell lung cancers (NSCLCs), oncogene-driven NSCLCs (including those driven by epidermal growth factor receptor – EGFR) are characterized by low mutational burdens and complex genomic landscapes. However, the clonal architecture and genomic landscape of the oncogene-driven NSCLCs in…
Gautam Kumar, Shweta Khandibharad, Shailza Singh
Non-small cell lung cancer (NSCLC) is the most prevalent subtype of lung cancer and a leading cause of cancer-related mortality worldwide. Literature evidences indicates a strong association between systemic inflammation, driven by cytokines such as Interleukin-6 (IL-6), and the development of NSCLC-associated…
Minglang GAO, Xiao LU, Bo HAO, Ning LI + 1 more
复合性小细胞肺癌（combined small cell lung cancer, CSCLC）是根据世界卫生组织2015年肺癌新病理分类，将SCLC与非小细胞肺癌（non-small cell lung cancer, NSCLC）成分混合而成的癌症，在神经内分泌肿瘤中被归类为SCLC的亚型。目前对于SCLC的研究主要集中于单一成分的纯SCLC，对于CSCLC的研究相对较少，且CSCLC临床罕见，尚无规范的治疗方案，对于CSCLC的临床病理特征及预后预测指标缺乏统一的认知，需要进一步观察疗效和预后。现报告1例CSCLC患者的诊疗经过，并对CSCLC的研究现状进行文献回顾。
Rédoane Daoudi
This is the second part of the previous review. In the previous review we suspected that Orai3 channels were involved in lung cancer and more precisely in several cancers. Here we confirm that calcium dysregulation is important for cancer development. in this paper we show that Orai3 is an upstream activator of AKT and…
Chengyuan Qian, Hong Liu, Yan Feng, Shenglan Meng + 2 more
Lung cancer as a second primary malignancy is increasingly common, but the clinical characteristics of second primary non-small cell lung cancer after cervix cancer (CC-NSCLC) in comparison with first primary non-small cell lung cancer (NSCLC1) is unknown. The Surveillance, Epidemiology and EndResults (SEER) cancer…
Lili Zhong, Jiaojiao Suo, Ya Wang, Jialong Han + 3 more
'Hao Wei' 'Jiang Zhu'] Background The NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology (NCCN guidelines) recommend radical resection for T1-2N0M0 patients with limited-stage small cell lung cancer (LS-SCLC). However, only about 5% of patients with small cell cancer (SCLC) were…
Authors not listed
Ensartinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, recently approved for the treatment of ALK-positive non-small cell lung cancer (NSCLC). In this study, density functional theory (DFT) calculations were employed to investigate the molecular structure, electronic properties, and thermodynamic…
Zhuo Wang, Qing Luo, Jie Wu, Li Lu + 11 more
Combined small-cell lung cancer (cSCLC) is a rare and aggressive subtype of small-cell lung cancer (SCLC) characterized by mixed histology comprising SCLC and non-small cell lung cancer (NSCLC) or large cell neuroendocrine carcinoma (LCNEC) components. Despite its histological heterogeneity and even poorer prognosis…
David Heppner, Tyler Beyett, Tatiana Shaurova, Calvin Pham + 7 more
Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better understand lazertinib inhibition at the molecular level, we determined crystal structures of lazertinib in complex with both WT and mutant EGFR and compared its…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Randa Mahran, Jonas N. Kapp, Salla Valtonen, Allison Champagne + 8 more
Mutated KRAS proteins are frequently expressed in some of the most lethal human cancers, thus having been a target of intensive drug discovery efforts for decades. Lately, KRAS(G12C) switch-II pocket (SII-P)-targeting covalent small molecule inhibitors have finally reached the clinical practice. Sotorasib (AMG-510) was…
Ayooluwa Ilesanmi, Gbenga Dairo, Toheeb Balogun, Bibiire Awoyale
Lung cancer is the cancer of the lung's epithelial cells typically characterized by difficult breathing, chest pain, blood-stained coughs, headache, and weight loss. If left unmanaged, lung cancer can spread to other body parts. While several treatment methods exist for managing lung cancer, exploring natural plant…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Chuang Niu, Ge Wang
Accurate risk assessment in lung cancer screening is critical for enabling early cancer detection and minimizing unnecessary invasive procedures. The Lung CT Screening Reporting and Data System (Lung-RADS) has been widely used as the standard framework for patient management and follow-up. Nevertheless, Lung-RADS faces…
Hailan Zhang, G D Song
Background: Lung cancer (LC) is a type of malignant neoplasm that originates in the bronchial mucosa or glands. As a clinically common nodule, solitary pulmonary nodules (SPNs) have a significantly higher probability of malignancy when they are larger than 8 mm in diameter. But there is also a risk of lung cancer when…